Physician profile
Paul Rea
NPI 1902907629
$1,449.02
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $139 · 2021: $314 · 2022: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $478.19 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $210.71 | 2019-2020 | |
| Maculogix, INC. | $141.12 | 2019 | |
| Glaukos Corporation | $124.91 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $124.24 | 2019 | |
| Allergan, INC. | $103.00 | 2022 | |
| Genzyme Corporation | $99.98 | 2019 | |
| Coopervision INC. | $96.07 | 2021 | |
| Avedro INC. | $29.94 | 2019 | |
| Sight Sciences, INC. | $23.62 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.